Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
Aaron S MansfieldJun Vivien YinPenelope BradburyDavid J KwiatkowskiShiven PatelLyudmila A BazhenovaPatrick FordeYanyan LouPaul DizonaLiza C VillaruzSusanne M ArnoldMaya KhalilHedy L KindlerMarianna KoczywasJose PachecoChristian RolfoBing XiaElizabeth MikulaLi ChenKashish PatelKatherine E R SmithLiang CaoGeoffrey ShapiroBrian A CostelloAlex AdjeiElad SharonJeffrey A MoscowWilliam ZamboniRaffit HassanPublished in: Lung cancer (Amsterdam, Netherlands) (2024)
The numeric difference in PFS between treatment groups was not statistically significant, likely related to a smaller than planned sample size. High levels of soluble mesothelin should potentially be considered to select against the use of mesothelin-targeting therapies in development that are neutralized by soluble mesothelin.